4
2
↑0
↓4
—2
Evidence suggests Magnesium maydecreaseConstipation.
6 studies (6 claims)
Emerging evidence
Typical effective dose 800 (800–800) mgacross 1 dosed study
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| addition of magnesium to infant formula | No effect - limited evidence to support | treat constipation | Human | — | Not mentioned | A narrative review on the diagnosis and management of constipation in infants.cited 2× |
| magnesium salts | Decreases - moderate evidence for | chronic constipation | Human | patients with chronic constipation | Not specified | Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review.cited 42× |
| standard laxatives such as macrogol/electrolytes and magnesium hydroxide | Decreases - recommended to prevent | Opioid-induced constipation (OIC) | Human | cancer patients treated with opioids | Not specified in the abstract. | Magnesium hydroxide versus macrogol/electrolytes in the prevention of opioid-induced constipation in incurable cancer patients: study protocol for an open-label, randomized controlled trial (the OMAMA study).cited 1× |
| magnesium hydroxide | No effect - will be assessed for | Rome IV criteria for constipation | Human | patients with incurable cancer starting with opioids for pain management | Not specified in the abstract. | Magnesium hydroxide versus macrogol/electrolytes in the prevention of opioid-induced constipation in incurable cancer patients: study protocol for an open-label, randomized controlled trial (the OMAMA study).cited 1× |
| oral magnesium supplementation | Decreases - experienced less | constipation | Human | patients undergoing cardiac surgery | 800 mg magnesium oxide (240 mg elemental magnesium per tablet, 2 tablets daily). | Oral magnesium supplementation reduces the incidence of gastrointestinal complications following cardiac surgery: a randomized clinical trial.cited 9× |
| supplementation with probiotics, prebiotics, symbiotics or magnesium | Decreases - Positive results included | constipation | Human | children with cerebral palsy | Not specified | Dietary and nutritional interventions in children with cerebral palsy: A systematic literature review.cited 3× |
| magnesium hydroxide (MH) | No effect - equally effective and safe | treating functional constipation | Human | children from 0.5 to 18 years of age | Not specified in the abstract. | Efficacy, safety, and acceptability of polyethylene glycol 3350 without electrolytes vs magnesium hydroxide in functional constipation in children from six months to eighteen years of age: A controlled clinical trial.cited 5× |
| magnesium hydroxide (MH) | No effect - can be considered first-line treatment | treating functional constipation | Human | children under 4 years of age | Not specified in the abstract. | Efficacy, safety, and acceptability of polyethylene glycol 3350 without electrolytes vs magnesium hydroxide in functional constipation in children from six months to eighteen years of age: A controlled clinical trial.cited 5× |